Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028045 | 0.89 | OPRM1 (0.35) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL4028041 | 0.89 | OPRM1 (0.35) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL13721487 | 0.89 | OPRM1 (0.35) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL4751549 | 0.86 | OPRM1 (0.34) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL4772539 | 0.86 | OPRM1 (0.34) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL4751548 | 0.86 | OPRM1 (0.34) | KDM1AOPRM1OPRD1KDM2B | |
| SCHEMBL4751428 | 0.86 | KIF11 (0.34) | — | |
| SCHEMBL4026066 | 0.84 | ESR1 (0.32) | KDM2B | |
| SCHEMBL4786324 | 0.84 | OPRM1 (0.32) | KDM1AOPRM1OPRD1 | |
| SCHEMBL4025458 | 0.84 | NPC1 (0.36) | KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1962846-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007059323-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KDM1A 3938/4885OPRM1 4219/4885OPRD1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.